Vitamin K antagonist

And I think that it's important that we are aware that if the patient is kept alive, at 70% of the time in therapeutic interval, then it is actually rather comparable as to both benefits and harms as to DOACs.

And that can be achieved through self-monitored VKA.

But overall, this is extremely difficult, cumbersome, and takes a lot of resources to achieve why most clinicians prefer using DOACs.

and also because of all these blood tests because, of course, the dosing is based on the RNR.

But there are specific conditions like mechanical valves and antiphospholipid syndrome that must have VKA.

If we go to the non-cardiobolic stroke, which for most patients will mean that simply they don't have AFib, you have to look at short-term versus and long-term because these are two different issues.

And I'm following very closely the ESO guidelines in what I'm saying and not just all guidelines.